Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Police & Firemen s Retirement System of New Jersey

Police & Firemen s Retirement System of New Jersey raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 18,963 shares of the biopharmaceutical company’s stock after acquiring an additional 212 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Alnylam Pharmaceuticals were worth $6,184,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Teacher Retirement System of Texas grew its position in shares of Alnylam Pharmaceuticals by 3.2% during the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after acquiring an additional 1,123 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Alnylam Pharmaceuticals by 33.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 95,796 shares of the biopharmaceutical company’s stock worth $31,238,000 after purchasing an additional 23,749 shares during the period. Simon Quick Advisors LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $222,000. Strs Ohio purchased a new position in Alnylam Pharmaceuticals during the 1st quarter worth $7,781,000. Finally, Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the sale, the executive vice president directly owned 25,231 shares in the company, valued at approximately $11,405,673.55. The trade was a 8.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 82,346 shares of company stock valued at $37,530,942 in the last quarter. Corporate insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.1%

ALNY opened at $449.16 on Friday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The stock has a market capitalization of $59.34 billion, a P/E ratio of -181.85 and a beta of 0.30. The business has a 50 day simple moving average of $458.80 and a 200-day simple moving average of $383.09.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several recent research reports. Piper Sandler reiterated an “overweight” rating and set a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Raymond James Financial assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Twenty-three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $482.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.